Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Juro Nakanishi is active.

Publication


Featured researches published by Juro Nakanishi.


Cancer Immunology, Immunotherapy | 2007

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

Juro Nakanishi; Yoshihiro Wada; Koichiro Matsumoto; Miyuki Azuma; Ken Kikuchi; Shoichi Ueda

PurposeThe programmed death-1 (PD-1)/B7-H1 (also called PD-L1) pathway negatively regulates T cell activation and has been suggested to play an important role in regulating antitumor host immunity. To investigate the clinical significance of B7-H1 expression to the tumor grade and postoperative prognosis of patients with urothelial cancer, we analyzed the relationship between B7-H1 expression and various clinicopathological features and postoperative prognosis.Experimental designSixty-five urothelial cancer cases were examined. B7-H1 expression in tumors and the numbers and phenotypes of tumor-infiltrating lymphocytes were evaluated by immunohistochemistry and flow cytometry.ResultsA substantial expression of B7-H1 was observed in all urothelial cancers investigated. Tumor specimens from patients with higher WHO grade or primary tumor classifications showed significantly higher percentages of tumor-associated B7-H1. Tumor-associated B7-H1 expression was significantly associated with a high frequency of postoperative recurrence and poor survival rate. Furthermore, multivariate analysis indicated that tumor-associated B7-H1 was more significant prognostic factor than WHO grade.ConclusionsOur results demonstrate that the aberrant expression of B7-H1 in urothelial cancer is associated with aggressive tumors, suggesting a regulatory role of tumor-associated B7-H1 in antitumor immunity. Therefore, the manipulation of tumor-associated B7-H1 may become a beneficial target for immunotherapy in human urothelial cancer.


BJUI | 2006

Mass screening for prostate cancer in patients with end‐stage renal disease: a comparative study

Yoshihiro Wada; Juro Nakanishi; Wataru Takahashi; Nobuyuki Kai; Yoshiharu Nakayama; Yasuyuki Yamashita; Jiro Honda; Shoichi Ueda

To determine the usefulness of prostate‐specific antigen (PSA) screening for prostate cancer in patients with end‐stage renal disease (ESRD), as although serum PSA is effective in the early detection of this cancer in the general population, there are few reports of its utility in patients with ESRD.


International Journal of Urology | 2006

Lower urinary tract dysfunction in type 1 familial amyloidotic polyneuropathy in Kumamoto, Japan.

Yoshihiro Wada; Yukio Ando; Nobuyuki Kai; Wataru Takahashi; Hiroaki Kikukawa; Juro Nakanishi; Jiro Honda; Yoshiteru Jinnouchi; Shoichi Ueda

Objective: To evaluate lower urinary tract dysfunction of type 1 familial amyloidotic polyneuropathy (FAP) patients in Kumamoto, Japan.


BJUI | 2007

Regional differences in the functional and biochemical properties of endothelin receptor subtypes in the rabbit prostatic urethra.

Yoshihiro Wada; Wataru Takahashi; Jamshid Latifpour; Gen Yamada; Nobuyuki Kai; Jiro Honda; Juro Nakanishi; Robert M. Weiss

To examine the regional differences in the functional (pharmacological) and biochemical properties of endothelin (ET) receptors in the rabbit prostatic urethra.


International Journal of Urology | 2006

Neurologic toxicity associated with interferon α therapy for renal cell carcinoma

Yoshihiro Wada; Tomohiro Kuwahara; Eiichiro Uyama; Juro Nakanishi; Wataru Takahashi; Jiro Honda; Hiroaki Kikukawa; Yoshiteru Jinnouchi; Shoichi Ueda

Abstract  A 67‐year‐old man received interferon α (IFN α) therapy for lung metastases of renal cell carcinoma (RCC). Multiple pulmonary metastases disappeared completely. However, neurological toxicity was detected by magnetic resonance imaging (MRI) as abnormal brain lesions. After discontinuation of IFN α therapy, his neurological symptoms and abnormal lesions on MRI disappeared completely. Complete remission of RCC has continued, and results of neurological study have remained normal for 5 years after discontinuation of IFN α therapy.


Urologia Internationalis | 2003

Effects of castration on nitric oxide-mediated relaxations in male rat corpus cavernosum smooth muscle.

Tomohiro Kuwahara; Yoshihiro Wada; Wataru Takahashi; Masaki Yoshida; Hitoshi Iwashita; Hiroaki Kikukawa; Juro Nakanishi; Shoichi Ueda

Background: The effects of castration on nitric oxide- mediated relaxations and nitric oxide synthase activity in male rat corpus cavernosum smooth muscles. Methods: Eight-week-old male rats were assigned to two groups: control (sham operated) and castrated animals. After 8 weeks, corpus cavernosum smooth muscle strips were mounted in an organ bath for isometric tension recordings. Electrical field stimulation (EFS) was applied to the strips precontracted with 30 µM phenylephrine. The microdialysis probe was inserted into the strip, and Krebs-Henseleit solution was perfused into the probe. The dialysate during EFS and cholinergic stimulation was collected, and the amount of NO–2/NO–3 (NOx) released in the dialysate was measured by the Greiss method. Sodium nitroprusside and carbachol were cumulatively added to the strips precontracted with 30 µM phenylephrine. Results: EFS caused frequency-dependent relaxations and NOx releases in the strips. Pretreatment with Nω-nitro-L-arginine (100 µM) and tetrodotoxin (1 µM) completely inhibited relaxations and NOx releases. The maximum relaxation in the castration group was significantly greater than that in the control group. The release of NOx was significantly greater in the castration group than in the control group. Sodium nitroprusside relaxed the tissues in both groups similarly. Carbachol failed either to relax the tissue or to increase the amount of NOx production in the tissue. Conclusion: The present data suggest that castration enhances nitric oxide synthase activity and nitric oxide-mediated relaxations in the male rat corpus cavernosum.


Archive | 2013

Renal Carcinoma Surveillance Counterpoint: Japan

Masatoshi Eto; Wataru Takahashi; Yoshiaki Kawano; Jiro Honda; Juro Nakanishi; Yoshihiro Wada

Huang et al. provide an excellent summary of contemporary renal cell carcinoma management, including the epidemiology, diagnosis, surgical treatment, systemic therapy, and strategies for follow-up [1]. We present our opinion, which slightly differs from that of Huang et al., based on recent reports and our experience at Kyushu University, Japan.


Cancer Chemotherapy and Pharmacology | 2007

Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer

Yoshihiro Wada; Ken Kikuchi; Wataru Takahashi; Jiro Honda; Juro Nakanishi; Koichiro Matsumoto; Tomohiro Kuwahara; Nobuyuki Kai; Hiroaki Kikukawa; Shoichi Ueda


The Journal of Urology | 2013

309 FREQUENT EXPRESSION OF C5AR IN METASTATIC RENAL CELL CARCINOMA (MRCC) AND THE BIOLOGICAL ROLE OF C5A-C5AR SYSTEM IN MRCC

Yoshihiro Maeda; Yoshihiro Wada; Yoshiaki Kawano; Ken Kikuchi; Wataru Takahashi; Jiro Honda; Kenichiro Tanoue; Juro Nakanishi; Fumiki Tanigawa; Junji Yatsuda; Takahisa Imamura; Masatoshi Eto


The Journal of Urology | 2012

444 ABERRANT EXPRESSION OF C5AR IN METASTATIC RENAL CELL CARCINOMA

Yoshihiro Maeda; Yoshihiro Wada; Yoshiaki Kawano; Ken Kikuchi; Wataru Takahashi; Jiro Honda; Juro Nakanishi; Takahisa Imamura; Masatoshi Eto

Collaboration


Dive into the Juro Nakanishi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge